Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam;Çoklu ilaç dirençli Acinetobacter baumannii menenjiti olgusunun yüksek doz ampisilin-sülbaktam ile başarιlι tedavisi

Mikrobiyoloji Bulteni

Volumn 42, Issue 2, 2008, Pages 353-358

  Sayin Kutlu, Selda ^a   Saçar, Suzan ^a   Süzer, Tuncer ^a   Cevahir, Nural ^a   Ökke, Demet ^a   Dirgen Çaylak, Selmin ^a   Turgut, Hüseyin ^a  

^a PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acinetobacter baumannii; Ampicillin sulbactam; Nosocomial meningitis

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; SULBACTAM; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AGED; ARTICLE; BACTERIAL MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID; CROSS INFECTION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; CEREBROSPINAL FLUID; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; SULBACTAM; TREATMENT OUTCOME;

EID: 52349089579     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection: mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103.
2. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993; 17: 843-9.
3. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997; 24: 932-5.
4. Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J Chemother 2006; 18: 589-602.
5. Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by Acinetobacter species. Indian J Med Sci 2006; 60: 351-60.
6. Jimenez-Mejias ME, Becerril B, Marquez-Rivas FJ, Pichardo C, Cuberos L, Pachon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000; 12: 970-1.
7. Smolyakov R, Borer A, Riesenber K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54: 32-8.
8. Ko WC, Lee HC, Chiang SR, at al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 2004; 53: 393-5.
9. Wang FD, Lin ML, Lee WS, Liu CY. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against gram-negative bacteria. Int J Antimicrob Agents 2004; 23: 590-5.
10. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13: 196-8.
11. Panchon-Ibanez MA, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem/cilastatin. Antimicrob Agents Chemother 2004; 48: 4479-81.
12. Song JY1, Kee SY1, Hwang IS, et al. In vitro activities of carbapenem/ sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrobial Chemother 2007; 60: 317-22.
13. Reid GE, Grim SA, Aldeza CA, et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th Informational Supplement M7-A6. 2005. CLSI, Wayne, PA.
15. Wang KW, Chang WN, Huang CR, et al. Post-neurosurgical nosocomial bacterial meningitis in adults: microbiology, clinical features, and outcomes. J Clin Neurosci 2005; 12: 647-50.
16. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328: 21-8.
17. Metan G, Alp E, Aygen B, Sumerkan B. Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis. Int J Antimicrob Agents 2007; 29: 112-3.
18. Sacar S, Turgut H, Toprak S et al. Retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006; 6: 43.
19. Fulnecky EJ, Wright D, Scheld WM, Kanawati L, Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005; 51: 249-51.
20. Trottier M, Segura PG, Namias N, King D, Pizano LR, Schulman CI. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J Burn Care Res 2007; 28: 248-54.
21. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525-30.
22. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002; 8: 144-53.
23. Shi ZY, Liu PY, Lau Y, Lin Y, Hu BS, Shir J-M. Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 1996; 24: 81-5.
24. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 270-1.
25. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21: 58-62.
26. Kendirli T, Aydin HI, Hacihamdioglu D, et al. Meningitis with multidrug-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. J Hosp Infect 2004; 56: 328.
27. Cawley MJ, Suh C, Lee S, Ackerman BH. Nontraditional dosing of ampicillin-sulbactam for multidrug resistant Acinetobacter meningitis. Pharmacotherapy 2002; 22: 527-32.